Colgate-Palmolive Company
CL
$89.82
-1.02%
Colgate-Palmolive Company is a global leader in the household and personal care industry, manufacturing oral care products, personal care items, and home care products sold in over 200 countries, with its namesake oral care line accounting for over 40% of total sales. The company also owns Hill's Pet Nutrition, a specialty pet food maker contributing nearly one-fourth of sales, and derives about 70% of its revenue from international markets, including almost half from emerging regions. Currently, the stock is under investor scrutiny as it navigates a post-pandemic normalization, with recent quarterly results showing strong revenue growth of 8.4% year-over-year, but the company faces challenges from input cost inflation and currency headwinds, while its defensive characteristics make it a favored rotation target in a volatile market.…
CL
Colgate-Palmolive Company
$89.82
Investment Opinion: Should I buy CL Today?
Rating: Hold. The stock is fairly valued with a trailing P/E of 29.9x, a 36% premium to the industry average, but justified by strong brand and cash generation. Analyst consensus is Buy with an average target of $98.95, implying 9% upside. However, margin pressure and high leverage warrant caution.
Sign up to view all
CL 12-Month Price Forecast
The AI model sees a balanced risk-reward. While the company's defensive nature and strong cash flow provide a floor, the valuation premium and margin pressures limit upside. A neutral stance is appropriate, with a slight bullish tilt if margins stabilize. Upgrades would require evidence of margin recovery and sustained growth, while downgrades would follow further margin erosion or a broader market sell-off.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Colgate-Palmolive Company's 12-month outlook, with a consensus price target around $98.95 and implied upside of +10.2% versus the current price.
Average Target
$98.95
0 analysts
Implied Upside
+10.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$87 - $110
Analyst target range
Colgate-Palmolive is covered by 20 analysts, with a consensus recommendation of 'Buy' and a mean rating of 2.05 (where 1 is Strong Buy and 5 is Sell). The average price target is $98.95, implying an upside of 9.0% from the current price of $90.75. The distribution of ratings includes 12 Buy, 6 Hold, and 2 Sell, indicating a moderately bullish sentiment. The target price range spans from $87.00 (low) to $110.00 (high), with the high target suggesting a 21.2% upside, likely assuming successful margin recovery and continued growth in emerging markets, while the low target implies a 4.1% downside, reflecting concerns about input cost inflation and competitive pressures. Recent ratings actions have been mostly positive, with Citigroup, UBS, and Rothschild & Co reiterating or upgrading to Buy, while Wells Fargo and Barclays maintain Equal Weight, indicating a stable but not overly enthusiastic outlook.
Bulls vs Bears: CL Investment Factors
Colgate-Palmolive presents a mixed picture: strong revenue growth and exceptional profitability metrics are offset by margin compression and a rich valuation. The bull case rests on the company's defensive appeal, robust cash flow, and analyst optimism, while the bear case highlights the premium valuation and rising leverage. Currently, the evidence slightly favors the bulls due to the company's proven resilience and growth in emerging markets, but the key tension is whether margin recovery can justify the premium multiple. If margins continue to decline, the stock could face significant de-rating.
Bullish
- Strong Revenue Growth: Q1 2026 revenue grew 8.4% YoY to $5.324B, driven by organic growth across Oral, Personal and Home Care and Pet Nutrition. This demonstrates the company's ability to grow despite a challenging macro environment.
- Exceptional ROE and Margins: ROE stands at 39.5%, reflecting efficient capital use, while gross margin remains high at 60.6%. These metrics indicate a strong competitive position and pricing power.
- Robust Free Cash Flow: TTM free cash flow is $3.767B, providing ample liquidity for dividends, debt reduction, and strategic investments. This supports the company's financial flexibility.
- Analyst Consensus Buy: With a consensus rating of 'Buy' and an average price target of $98.95, analysts see 9% upside. Recent upgrades from Citigroup and UBS reinforce positive sentiment.
Bearish
- Margin Compression: Net margin fell to 12.1% in Q1 2026 from 14.1% a year ago, and operating margin contracted to 21.7% from 22.2%. Input cost inflation and higher marketing spend are pressuring profitability.
- High Valuation Premium: Trailing P/E of 29.9x is 36% above the industry average of 22x. This premium leaves little room for error and could lead to multiple compression if growth disappoints.
- Elevated Debt Levels: Debt-to-equity ratio of 147.9% is high for a consumer staples company. While interest coverage is adequate at 18.6x, leverage increases financial risk.
- Negative PEG Ratio: PEG ratio of -1.19 signals potential overvaluation if earnings decline as expected. The market's growth expectations may be too optimistic given recent margin trends.
CL Technical Analysis
Colgate-Palmolive's stock is currently in a recovery phase after a significant pullback, trading at $90.75 as of August 28, 2026, which is 91.4% of its 52-week range (low of $74.55, high of $99.33). Over the past year, the stock has gained 8.79%, but it has underperformed the S&P 500, which rose 18.56% over the same period, indicating relative weakness. The stock's 6-month price change is -8.46%, reflecting a sharp decline from its April peak, but it has since stabilized, with the current price sitting near the midpoint of its 52-week range, suggesting a potential value opportunity if support holds.
Beta
0.33
0.33x market volatility
Max Drawdown
-17.5%
Largest decline past year
52-Week Range
$75-$99
Price range past year
Annual Return
+6.8%
Cumulative gain past year
| Period | CL Return | S&P 500 |
|---|---|---|
| 1m | -1.6% | +2.7% |
| 3m | +1.8% | +1.0% |
| 6m | -5.7% | +12.0% |
| 1y | +6.8% | +18.9% |
| ytd | +15.6% | +12.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CL Fundamental Analysis
Colgate-Palmolive reported Q1 2026 revenue of $5.324 billion, up 8.4% year-over-year, driven by strong organic growth across its Oral, Personal and Home Care segment ($4.034 billion) and Pet Nutrition ($1.196 billion). However, the company's net income of $646 million in Q1 2026 was down from $690 million in Q1 2025, reflecting a net margin of 12.1% versus 14.1% a year earlier, due to higher input costs and increased marketing investments. The company's gross margin remained robust at 60.6%, but operating margin contracted to 21.7% from 22.2% in the prior year, indicating margin pressure. On the balance sheet, Colgate has a debt-to-equity ratio of 147.9%, which is high for a consumer staples company, but its interest coverage of 18.6x and free cash flow of $3.767 billion (TTM) provide ample cushion. The company's ROE of 39.5% is exceptional, reflecting its efficient use of equity, though it is partly driven by high leverage.
Quarterly Revenue
$5.3B
2026-03
Revenue YoY Growth
+8.4%
YoY Comparison
Gross Margin
60.6%
Latest Quarter
Free Cash Flow
$3.8B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CL Overvalued?
Given Colgate's positive net income, the trailing P/E ratio of 29.9x is the primary valuation metric, while the forward P/E of 22.1x implies the market expects earnings growth of about 35% over the next year, which seems optimistic given the company's recent margin compression. Compared to the industry average P/E of 22x (based on the provided data), Colgate trades at a 36% premium, which may be justified by its strong brand portfolio, global reach, and consistent cash generation, but it leaves little room for error. Historically, Colgate's P/E has ranged from 20.7x to 41.8x over the past five years, and the current 29.9x is near the middle of that range, suggesting the stock is fairly valued relative to its own history, though the PEG ratio of -1.19 (negative due to expected earnings decline) signals potential overvaluation if growth stalls.
PE
29.9x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 21x~32x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
17.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks include a high debt-to-equity ratio of 147.9%, which could strain cash flows if interest rates rise. However, interest coverage of 18.6x and TTM free cash flow of $3.767B provide a cushion. Margin compression is a concern, with net margin down to 12.1% from 14.1% YoY, driven by input cost inflation and increased marketing spend. The payout ratio of 85.5% leaves limited room for dividend growth without impacting balance sheet flexibility.
FAQ
Key risks include margin compression from input cost inflation, with net margin down to 12.1% from 14.1% YoY. High leverage (debt-to-equity of 147.9%) increases financial risk, though interest coverage is adequate. Competitive pressures in the household and personal care sector could erode market share. Macro risks include currency fluctuations, as 70% of revenue comes from international markets, and a potential global economic slowdown affecting consumer spending.
Analysts have a consensus Buy rating with an average price target of $98.95, implying 9% upside from the current price of $90.75. The bull case targets $110 (21% upside) if margins recover and growth accelerates, while the bear case targets $87 (4% downside) if margin pressure persists. The base case, with a 50% probability, sees the stock reaching the average target. The most likely scenario is moderate growth with stable margins, leading to a gradual appreciation.
CL trades at a trailing P/E of 29.9x, a 36% premium to the industry average of 22x, indicating the market is paying a premium for its defensive qualities and brand strength. The forward P/E of 22.1x implies expected earnings growth of about 35%, which seems optimistic given recent margin compression. Historically, the stock's P/E has ranged from 20.7x to 41.8x, so the current level is near the middle, suggesting fair value relative to its own history. However, the negative PEG ratio of -1.19 signals potential overvaluation if growth stalls.
CL offers a defensive profile with a beta of 0.327 and a dividend yield of 2.85%, making it attractive for income-focused investors. However, the trailing P/E of 29.9x is 36% above the industry average, and the negative PEG ratio suggests potential overvaluation. With analyst targets implying 9% upside, the risk-reward is balanced. It's a good buy for those seeking stability and willing to accept modest returns, but growth investors may find better opportunities elsewhere.
CL is better suited for long-term investment due to its defensive nature, low beta of 0.327, and consistent dividend payments. The stock's volatility is low, making it less attractive for short-term trading. With a payout ratio of 85.5%, the dividend is well-covered, and the company's global brand portfolio provides earnings visibility. A minimum holding period of 3-5 years is recommended to ride out market cycles and benefit from compounding dividends.